SGLT2 Inhibitor: Not a Traditional Diuretic for Heart Failure.

SGLT2 Inhibitor: Not a Traditional Diuretic for Heart Failure.
Cell Metab. 2020 Jul 07;32(1):13-14
Authors: Verma A, Patel AB, Waikar SS
Abstract
Recent studies have shown impressive cardiovascular health benefits in individuals treated with SGLT2 inhibitors (SGLT2i) regardless of diabetic status. The underlying mechanisms driving these benefits are not well understood. Recently in Circulation, Griffin et al. (2020) reported the first human study investigating the diuretic effect of empagliflozin.
PMID: 32640243 [PubMed - in process]

Source: Cell Metabolism - July 6, 2020 Category: Cytology Authors: Verma A, Patel AB, Waikar SS Tags: Cell Metab Source Type: research